Inventor · disambiguated record
Robert C. Pordy
Also filed as: PORDY ROBERT · PORDY ROBERT C
10 granted patents·24 pending applications·70 citations·filing 2012–2025
89Inventor score
Files withREGENERON PHARMA21SANOFI BIOTECHNOLOGY10BESSAC LAURENCE1REGENERAN PHARMACEUTICALS INC1SANOFI SA1
Top patents by PatentIndex Score
34 records- 0194US9724411B2Methods for treating hypercholesterolemia and reducing LDL-C using antibodies to PCSK9REGENERON PHARMA·Filed 2013·Granted Aug 8, 2017·15 cites·32 claims
- 0291US11904017B2Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumabREGENERON PHARMA·Filed 2020·Granted Feb 20, 2024·3 cites·20 claims
- 0391US11306155B2Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibodySANOFI BIOTECHNOLOGY·Filed 2019·Granted Apr 19, 2022·5 cites·14 claims
- 0490US10772956B2Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumabREGENERON PHARMA·Filed 2016·Granted Sep 15, 2020·8 cites·17 claims
- 0588US10544232B2Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibodySANOFI BIOTECHNOLOGY·Filed 2015·Granted Jan 28, 2020·9 cites·16 claims
- 0688US10111953B2Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)REGENERON PHARMA·Filed 2014·Granted Oct 30, 2018·15 cites·12 claims
- 0784US10428157B2Dosing regimens for use with PCSK9 inhibitorsSANOFI BIOTECHNOLOGY·Filed 2014·Granted Oct 1, 2019·8 cites·13 claims
- 0883US11248044B2Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitorREGENERAN PHARMACEUTICALS INC·Filed 2019·Granted Feb 15, 2022·5 cites·27 claims
- 0982US2025332254A1Methods for treating patients with familial hypercholesterolemiaREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1082US2025059300A1METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH) WITH AN ANTI-PCSK9 ANTIBODYSANOFI BIOTECHNOLOGY·Filed 2024·Application pending·0 cites
- 1180US10934349B2Methods for increasing lean body mass with resistance training and a GDF8 inhibitor that is an anti-GDF8 antibodyREGENERON PHARMA·Filed 2016·Granted Mar 2, 2021·2 cites·29 claims
- 1276US2024261400A1Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumabREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1375US2025109191A1Methods for altering body composition by administering a gdf8 inhibitor and an activin a inhibitorREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1474US2024390489A1Methods of increasing strength and functionality with gdf8 inhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1574US2023000976A1Methods for treating patients with familial hypercholesterolemiaREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1673US2022315669A1METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH) WITH AN ANTI-PCSK9 ANTIBODYSANOFI BIOTECHNOLOGY·Filed 2022·Application pending·0 cites
- 1771US2024197870A1Methods for treating patients with refractory hypercholesterolemiaREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1867US12029788B2Methods for increasing lean body mass with an exercise regimen and a GDF8 inhibitor that is an anti-GDF8 antibodyREGENERON PHARMA·Filed 2021·Granted Jul 9, 2024·0 cites·26 claims
- 1966US2022119514A1Methods for altering body composition by administering a gdf8 inhibitor and an activin a inhibitorREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2062US2013064834A1Methods for treating hypercholesterolemia using antibodies to pcsk9REGENERON PHARMA·Filed 2012·Application pending·0 cites
- 2162US2020255544A1Methods for treating high cardiovascular risk patients with hypercholesterolemiaSANOFI BIOTECHNOLOGY·Filed 2019·Application pending·0 cites
- 2261US2022072127A1Methods for treating patients with refractory hypercholesterolemiaREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 2361US2022144969A1Methods for reducing cardiovascular riskSANOFI BIOTECHNOLOGY·Filed 2021·Application pending·0 cites
- 2460US2020061189A1Methods for Treating Patients with Familial HypercholesterolemiaREGENERON PHARMA·Filed 2019·Application pending·0 cites
- 2557US2017296657A1Methods for Treating Hypercholesterolemia and Reducing LDL-C Using Antibodies to PCSK9REGENERON PHARMA·Filed 2017·Application pending·0 cites
- 2653US2018296672A1Methods for Treating Patients with Hypercholesterolemia that is not Adequately Controlled by Moderate-Dose Statin TherapyREGENERON PHARMA·Filed 2018·Application pending·0 cites
- 2753US2017312359A1Methods for treating patients with familial hypercholesterolemiaREGENERON PHARMA·Filed 2017·Application pending·0 cites
- 2850US2023272112A1Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemiaREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 2950US2020024364A1Dosing regimens for use with pcsk9 inhibitorsSANOFI BIOTECHNOLOGY·Filed 2019·Application pending·0 cites
- 3049US2015231236A1Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapyREGENERON PHARMA·Filed 2015·Application pending·0 cites
- 3143US2019292273A1Methods for reducing cardiovascular riskSANOFI BIOTECHNOLOGY·Filed 2019·Application pending·0 cites
- 3243US2015140002A1Use of a pcsk9 inhibitor to treat hyperlipidemiaSANOFI SA·Filed 2014·Application pending·0 cites
- 3339US2016137746A1Methods for treating high cardiovascular risk patients with hypercholesterolemiaSANOFI BIOTECHNOLOGY·Filed 2015·Application pending·0 cites
- 3435US2015284473A1Methods for reducing cardiovascular riskBESSAC LAURENCE·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Robert C. Pordy files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →